The Federal Circuit affirmed rejection of a reissue patent application that tried to broaden claims beyond the original patent’s single disclosed embodiment, holding that reissue claims must be directed to the same invention explicitly described in the original patent—not to undisclosed altern
The Federal Circuit vacated the PTAB’s IPR decisions upholding Medtronic’s sacral nerve stimulation patents, finding the Board committed a fundamental error by limiting the motivation-to-combine inquiry to the specific application context of the primary reference rather than the full cla
The Federal Circuit reversed the dismissal of an induced patent infringement suit on res judicata grounds, holding that a prior judgment on direct infringement claims does not preclude a subsequent suit for induced infringement when the induced infringement claims are based on different operative fa
The Federal Circuit affirmed PTAB’s holding that Medytox’s botulinum toxin patents were not enabled across their full claimed scope, and clarified that PTAB preliminary guidance under the motion-to-amend pilot program is non-binding.
The Federal Circuit affirmed rejection of a patent application covering a hypertension treatment method, holding that discovering an unexpected mechanism through which known drugs achieve a known result does not overcome a prima facie obviousness case rooted in inherency.
The Federal Circuit affirmed PTAB’s decision to disregard Parus Holdings’ evidence in IPR proceedings, holding that a patent owner’s attempt to incorporate arguments by reference through voluminous exhibits violates PTAB procedural rules and the APA does not require the Board to ov
The Federal Circuit affirmed that a nonparty who shared key design elements for an expandable hose with the named inventor at a pre-filing meeting was a co-inventor who should have been listed on the patents, and that his testimony was adequately corroborated by physical prototypes and documentary e
The Federal Circuit reversed the PTAB’s reliance on commercial success as a secondary consideration of nonobviousness for car floor mat patents, holding that evidence of commercial success must be linked to the claimed combination as a whole, not to a single feature that was already present in
The Federal Circuit reversed the PTAB’s obviousness ruling on a drug delivery device patent, holding that the Board misapplied the analogous art test by comparing a prior art reference to another prior art reference rather than to the challenged patent—an IPR petitioner bears the burden of sho
The Federal Circuit reversed a district court’s addition of a joint inventor to a bacon-precooking patent, holding that contributing a preheating concept—when that concept was already known and not the novel element of the claimed invention—is an ‘insignificant’ contribution that d